Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.
Zhiwei LiXiaona FanDan JiangQingwei LiChao LiuDan WangNa LiHengzhen LiZhuo ChenHongzhen TangChangjie LouHaitao XuChao ZhanYuandi DongZhigang MaGuangyu WangChunhui ZhangHaibo LuTongsen ZhengYan-Qiao ZhangPublished in: The oncologist (2024)
The alternating sequential administration of the NS and GemOx regimens may be a novel approach for first-line chemotherapy in patients with advanced PDAC requiring further study (ClinicalTrials.gov Identifier: ChiCTR1900024867).